Additionally, serum FGF21 levels are elevated in patients with nonalcoholic fatty liver disease with subclinical atherosclerosis, and baseline level of FGF21 is an independent predictor of atherosclerotic cardiovascular disease and represents a novel biomarker for primary prevention in the general population (36). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.